MedTrace Logo

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

NCT02925702 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 161

Last updated 2020-01-27

No results posted yet for this study

Summary

PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with radium-223.

Conditions

Interventions

DRUG

Radium 223 55mBq/Kg every 4 weeks intravenously

Radium-223 55kBq/kg infusion IV every 4 weeks

Sponsors & Collaborators

  • Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

    collaborator OTHER

  • Centro Nacional de Investigaciones Oncologicas CARLOS III

    lead OTHER

Principal Investigators

  • David Olmos, MD · CNIO-Centro Nacionald e Investigaciones Oncológicas

  • Elena Castro, MD · CNIO-Centro Nacionald e Investigaciones Oncológicas

  • Rafael Morales, MD · Hospital Vall d'Hebron

  • Maria Isabel Saez, MD · Hospital Universitario Virgen de la Victoria

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-01-31
Completion
2020-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02925702 on ClinicalTrials.gov